Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesDo recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Oncology (Karger), 09/08/09
Hashimoto K et al. – Recurrent pancreatic cancer after surgery and pancreatic cancer with primary metastasis can be similarly categorized in clinical trials.
Methods- 326 patients (65 recurrent and 261 metastatic patients who received gemcitabine monotherapy as 1st-line tx for advanced pancreatic cancer
- Recurrent patients had a significantly longer time to tx failure and survival (medians, 138 and 77 d, respectively) compared to metastatic patients (medians, 270 and 185 d, respectively
- Poor Karnofsky PS (< 80), presence of liver or peritoneal metastasis, elevated LDH (> 220 U/l), elevated alkaline phosphatase (>330 U/l), and elevated CRP (>1 mg/dl) were correlated with short survival
- Recurrent or metastatic ds was not correlated with survival
- Leukopenia was more frequent in the recurrent group
- RR were similar in the recurrent and metastatic groups
Related Articles
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Relevance Score: 95%
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Journal of Clinical Oncology, 11/13/09
Relevance Score: 93%
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09
Relevance Score: 91%
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 91%
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: Case Report and review of the literature
World Journal of Surgical Oncology, 12/17/09
Liver transplantation for primary hepatic leiomyosarcoma: a case report and review of the literatures
Medical Oncology, 12/16/09
Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma
Cancer, 12/15/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/18/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor